An article in the Oct. 17, 2008, issue of BioWorld Today should have characterized Novacea Inc.'s Asentar as an oral formulation of calcitriol, which was combined with Taxotere in a previous prostate cancer study.

Editor's note: The correction has been made in BioWorld Online.